Overview
LBRX market data
Price History
LBRX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for LBRX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.Benzinga · Jul 22, 2026, 5:55 PM
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in SchizophreniaGlobenewswire Inc · Jul 22, 2026, 12:15 PM
8-K filing — LB PHARMACEUTICALS INC (LBRX)SEC EDGAR · Jul 22, 2026, 12:14 PM
LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027Benzinga · Jul 22, 2026, 12:02 PM
BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46Benzinga · Jul 21, 2026, 9:34 AM
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jul 10, 2026, 9:15 PM
LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) EstimateBenzinga · May 12, 2026, 9:10 PM